Coronado Biosciences, Inc. (NASDAQ: CNDO) is a company concerned with creation of biologic agents for the management of diseases such as cancer. Its product candidates are focused on clinical development for bowel disease, sclerosis, and leukemia. The company recently reported its 2012 third quarter results. It recorded net losses of $5.9 million and $18.9 million for the three and nine months ended September 30, 2012, respectively..........